|
|
|
|
LEADER |
01000caa a22002652c 4500 |
001 |
NLM186638213 |
003 |
DE-627 |
005 |
20250210052423.0 |
007 |
tu |
008 |
231223s2008 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed25n0622.xml
|
035 |
|
|
|a (DE-627)NLM186638213
|
035 |
|
|
|a (NLM)19238792
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Morcos, Paul A
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Vivo-Morpholinos
|b a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues
|
264 |
|
1 |
|c 2008
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 17.03.2009
|
500 |
|
|
|a Date Revised 07.06.2018
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a We have developed a new transporter structure that provides effective delivery of Morpholino antisense oligomers into a wide variety of tissues in living mice. This transporter comprises a dendritic structure assembled around a triazine core which serves to position eight guanidinium head groups in a conformation effective to penetrate cell membranes. This transporter structure is conjugated to a Morpholino oligomer to form a delivery-enabled product referred to as a Vivo-Morpholino. Vivo-Morpholinos are shown to effectively enter and function within cultured cells in the presence of 100% serum using a rigorous positive test system based on correction of a defined splicing error in a pre-messenger RNA. In addition, Vivo-Morpholinos are demonstrated to enter into a wide variety of tissues in a similar positive test system in transgenic mice, as evidenced by correction of the targeted splicing error in all tissues assessed, including near-complete splice correction in the small intestine, colon, stomach, liver kidney, and a number of muscles. Finally, Vivo-Morpholinos, which target the exon-skipping of exon 23 harboring a premature termination codon in the mdx mouse model, effectively restore the reading frame of dystrophin and restore expression of a functional dystrophin protein
|
650 |
|
4 |
|a Journal Article
|
650 |
|
7 |
|a Dystrophin
|2 NLM
|
650 |
|
7 |
|a Endo-Porter
|2 NLM
|
650 |
|
7 |
|a Oligonucleotides, Antisense
|2 NLM
|
650 |
|
7 |
|a Peptides
|2 NLM
|
650 |
|
7 |
|a Triazines
|2 NLM
|
650 |
|
7 |
|a Green Fluorescent Proteins
|2 NLM
|
650 |
|
7 |
|a 147336-22-9
|2 NLM
|
650 |
|
7 |
|a Guanidine
|2 NLM
|
650 |
|
7 |
|a JU58VJ6Y3B
|2 NLM
|
700 |
1 |
|
|a Li, Yongfu
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Jiang, Shan
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1991
|g 45(2008), 6 vom: 25. Dez., Seite 613-4, 616, 618 passim
|w (DE-627)NLM012627046
|x 1940-9818
|7 nnas
|
773 |
1 |
8 |
|g volume:45
|g year:2008
|g number:6
|g day:25
|g month:12
|g pages:613-4, 616, 618 passim
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_21
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_50
|
912 |
|
|
|a GBV_ILN_60
|
912 |
|
|
|a GBV_ILN_62
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_99
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_227
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_618
|
912 |
|
|
|a GBV_ILN_640
|
912 |
|
|
|a GBV_ILN_754
|
912 |
|
|
|a GBV_ILN_2001
|
912 |
|
|
|a GBV_ILN_2002
|
912 |
|
|
|a GBV_ILN_2003
|
912 |
|
|
|a GBV_ILN_2005
|
912 |
|
|
|a GBV_ILN_2006
|
912 |
|
|
|a GBV_ILN_2007
|
912 |
|
|
|a GBV_ILN_2008
|
912 |
|
|
|a GBV_ILN_2009
|
912 |
|
|
|a GBV_ILN_2010
|
912 |
|
|
|a GBV_ILN_2012
|
912 |
|
|
|a GBV_ILN_2015
|
912 |
|
|
|a GBV_ILN_2018
|
912 |
|
|
|a GBV_ILN_2023
|
912 |
|
|
|a GBV_ILN_2035
|
912 |
|
|
|a GBV_ILN_2040
|
912 |
|
|
|a GBV_ILN_2060
|
912 |
|
|
|a GBV_ILN_2099
|
912 |
|
|
|a GBV_ILN_2105
|
912 |
|
|
|a GBV_ILN_2121
|
912 |
|
|
|a GBV_ILN_2470
|
951 |
|
|
|a AR
|
952 |
|
|
|d 45
|j 2008
|e 6
|b 25
|c 12
|h 613-4, 616, 618 passim
|